68
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review

, , , , , , , , , & show all
Pages 5429-5434 | Published online: 09 Dec 2021

Figures & data

Figure 1 Hematoxylin-Eosin (HE) staining and immunohistochemistry of the OCCC. (A) HE staining determined it was an ovarian cancer; Magnification: 200X. (B) Positive of Napsin A determined it was an OCCC. Magnification: 200X. (C) The patient’s tumor had positive expression of PD-L1 (tumor proportion score of 10%). Magnification: 100X.

Figure 1 Hematoxylin-Eosin (HE) staining and immunohistochemistry of the OCCC. (A) HE staining determined it was an ovarian cancer; Magnification: 200X. (B) Positive of Napsin A determined it was an OCCC. Magnification: 200X. (C) The patient’s tumor had positive expression of PD-L1 (tumor proportion score of 10%). Magnification: 100X.

Figure 2 Magnetic resonance imaging results of pelvic cavity, pelvic floor peritoneum and abdominal wall one month after surgery (AC), at recurrence (DF), four months (GI) and eight months (JL) after everolimus plus Toripalimab. The yellow arrow represents the lesion.

Figure 2 Magnetic resonance imaging results of pelvic cavity, pelvic floor peritoneum and abdominal wall one month after surgery (A–C), at recurrence (D–F), four months (G–I) and eight months (J–L) after everolimus plus Toripalimab. The yellow arrow represents the lesion.